Whole Body Vibration in Chronic Obstructive Pulmonary Disease (COPD)

Status Recruiting

Clinical Trial Summary

The whole body vibration offers better treatment adherence among the elderly, minimizing effort and additional stress to the cardiovascular system and skeletal muscles compared to conventional exercise programs.

Hypothesis: Patients with COPD undergoing a training program on the whole body vibration show better performance in the 6MWT and improvement in muscle strength.

Clinical Trial Description

In the elderly and in COPD patients weight loss includes sarcopenia, resulting from aging itself or due to disuse or disease states associated with and represents the reduction in muscle mass, leading to decreased strength and endurance, with repercussions on the functional abilities of the same. It reduces the power and muscle strength with aging which represent decreasing to carry out daily physical tasks.

In COPD, exacerbations worsen the loss of muscle mass, affecting the respiratory and peripheral muscles, exercise capacity and survival rates, and in the case of severe malnutrition in advanced cases of the disease, the implications of this state are disability which occur between 10-15% in those with mild obstruction and 25% in moderate to severe obstructive and are associated with worse prognosis.

The whole body vibration could be an efficient combination of training methods for elderly patients and is based on the generation of sinusoidal vibrations offered by a platform, which stimulates the muscle spindles resulting in activation of neurons α engines and develop muscle contractions, presenting itself as an alternative to conventional treatment for muscular endurance as well as improving physical fitness ;

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease (COPD)
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT01649310
Study type	Interventional
Source	Universidade Federal de Pernambuco
Contact	Patricia Marinho Patricia Marinho, PhD
Phone	55 81 21268496
Email	patmarinho@yahoo.com.br
Status	Recruiting
Phase	N/A
Start date	February 2012
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03282019` - Study of Long-term HFNC for COPD Patients With HOT	N/A
Completed	`NCT05573464` - A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease	Phase 3
Recruiting	`NCT06040086` - Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations	Phase 3
Not yet recruiting	`NCT06376994` - Multi-Center Clean Air Randomized Controlled Trial in COPD	Phase 3
Completed	`NCT02728674` - Management of Patients With Respiratory Symptoms in Sweden	N/A
Completed	`NCT02926534` - Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan	N/A
Completed	`NCT02797392` - Feasibility of a Preventive Program Against Lifestyle Related Diseases	N/A
Recruiting	`NCT02415478` - Bronchioscopic Lung Volume Reduction (BLVR)	N/A
Completed	`NCT02512510` - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT03487406` - Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)	Phase 2
Completed	`NCT02518139` - A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT02774226` - Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease	Phase 2
Completed	`NCT02459080` - Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Withdrawn	`NCT01908933` - Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema	Phase 3
Completed	`NCT01893476` - A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management	N/A
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01908140` - Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Phase 3
Completed	`NCT01701869` - Microbiology & Immunology of the Chronically-inflamed Airway	N/A
Recruiting	`NCT02527486` - Seoul National University Airway Registry	N/A
Withdrawn	`NCT01377428` - Efficacy of Indacaterol 150 µg Versus Formoterol	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Whole Body Vibration in Chronic Obstructive Pulmonary Disease (COPD) Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms